VaxEquity
- Company typePrivate
- Founded2020
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
VaxEquity firmographics
Firmographics- Name
- VaxEquity
- Website
- https://vaxequity.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
VaxEquity industry classification
Industry- Product category
- Biopharmaceuticals / RNA Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
Keywords
Where VaxEquity is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
VaxEquity business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
VaxEquity product offering
Product offeringCore offering
VaxEquity is a biotechnology company developing RNA-based vaccines and therapeutics using proprietary self-amplifying RNA (saRNA) technology. The company's core focus is optimizing scalable saRNA production to enable rapid clinical development and improve global vaccine availability, with an active candidate influenza vaccine advancing through manufacturing process optimization in collaboration with CPI, supported by an Innovate UK grant.
Product overview
VaxEquity is a biotechnology company developing RNA-based vaccines and therapeutics. Their core technology focuses on self-amplifying RNA (saRNA) for vaccine development. The company is working on an influenza vaccine candidate with manufacturing optimization support from CPI, funded by an Innovate UK grant of approximately £700K. Their pipeline centers on saRNA production to improve global vaccine availability.
Differentiator
Problem solved
Functional benefit
Products and services
- RNA Vaccines and Therapeutics
- Influenza Vaccine Candidate
Quantifiable outcome
- Rapid clinical development enabled through optimized saRNA production processes
Companies that use VaxEquity
Customer profileSegments1 record
Ideal customer profiles2 records
VaxEquity technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
VaxEquity partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CPI (Centre for Process Innovation)coreVaxEquity partnered with CPI (Centre for Process Innovation) to advance manufacturing processes for RNA vaccines and therapeutics. The collaboration focuses on optimizing saRNA production conditions for a candidate influenza vaccine to enable rapid clinical development and improve global vaccine availability. This partnership is supported by an Innovate UK grant of approximately £700K.
Scale indicators1 record
Recent moves4 records
Expansion highlights3 records
VaxEquity competitors and assessment
Company assessmentDirect peers
- Arcturus Therapeutics: Arcturus is the most direct peer; it is a clinical-stage company specializing in self-amplifying mRNA (saRNA) vaccine and therapeutic platforms with a comparable technology base to VaxEquity's saRNA focus.
- CureVac: CureVac develops mRNA-based vaccines and therapeutics across infectious disease and oncology, competing in the same RNA modality and target indications as VaxEquity, with broader pipeline scale.
Broad incumbents
- Moderna: Moderna is the dominant commercial mRNA vaccine and therapeutics company and has publicly advanced saRNA programs; it operates as the broad incumbent whose scale, manufacturing, and clinical data set the competitive bar for emerging RNA players.
- BioNTech: BioNTech is a leading mRNA therapeutics and vaccine company with infectious-disease and oncology programs; it competes for the same influenza-vaccine market VaxEquity targets and is a likely partner or acquirer of niche RNA platforms.
- Translate Bio (Sanofi): Translate Bio, acquired by Sanofi, focuses on mRNA therapeutics for infectious disease and rare diseases and represents an established mRNA platform relevant to VaxEquity's manufacturing and clinical-development positioning.
Emerging players
- Ethris: Ethris is a clinical-stage mRNA therapeutics company with a focus on respiratory and rare-disease applications; it overlaps with VaxEquity on modality and respiratory delivery but is at a later clinical stage.
- eTheRNA Immunotherapies: eTheRNA is a Belgium-based mRNA and saRNA immunotherapies developer targeting infectious disease and oncology; it is a comparable emerging European peer using self-amplifying RNA constructs.
- Scancell: Scancell is a UK-based clinical-stage biotech developing DNA and mRNA-based vaccines for cancer and infectious disease; it overlaps with VaxEquity's UK base and nucleic-acid vaccine modality.
Others
- Touchlight (now Lonza DNA): Touchlight is a UK-based CDMO with enzymatic DNA and nucleic-acid manufacturing capabilities serving vaccine developers; it is comparable as an enabling manufacturing-services peer rather than a direct competitor.
- CPI (Centre for Process Innovation): CPI is a UK process-innovation Catapult and current VaxEquity co-development partner for saRNA manufacturing scale-up; it is included as an ecosystem/partner enabler rather than a competing product company.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat1 record
Key risks5 records
Key highlights5 records
Customer concentration
VaxEquity social profiles
Digital presenceVaxEquity financial estimates
Financial estimateRevenue estimate
Valuation estimate
VaxEquity leadership team
Management profileNumber of profiles
VaxEquity funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VaxEquity M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VaxEquity
What does VaxEquity do?
VaxEquity is a biotechnology company developing RNA-based vaccines and therapeutics using proprietary self-amplifying RNA (saRNA) technology. The company's core focus is optimizing scalable saRNA production to enable rapid clinical development and improve global vaccine availability, with an active candidate influenza vaccine advancing through manufacturing process optimization in collaboration with CPI, supported by an Innovate UK grant.
Is VaxEquity a public or private company?
VaxEquity is a private company. It is classified as venture growth investor backed and is currently operating.
When was VaxEquity founded?
VaxEquity was founded in 2020. It employs 11 to 50 people.
Where is VaxEquity based?
VaxEquity is headquartered in Cambridge, United States, in the North America region.
Who are VaxEquity's main competitors?
Direct peers on record are Arcturus Therapeutics and CureVac. Broad incumbents are Moderna, BioNTech and Translate Bio (Sanofi). Emerging players are Ethris, eTheRNA Immunotherapies and Scancell. Others are Touchlight (now Lonza DNA) and CPI (Centre for Process Innovation).
Does VaxEquity have an API?
No public API is recorded for VaxEquity.
What industry is VaxEquity in?
VaxEquity's product category is Biopharmaceuticals / RNA Therapeutics. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 541714 and its SIC code is 2836.